Opia Technologies

Executive Summary

Opia Technologies is a Paris-based private medical device company founded in 2016, specializing in ophthalmology. The company develops innovative, proprietary devices for ocular surface diagnosis and non-invasive drug delivery, covering the full device lifecycle from design to regulatory compliance under ISO 13485 certification. With a focus on addressing unmet needs in eye care, Opia aims to improve patient outcomes through advanced diagnostic tools and needle-free drug delivery systems. While still in a relatively early stage, the company has built a strong regulatory foundation and is poised to enter clinical and commercial phases. Given the growing prevalence of ocular surface diseases and the demand for less invasive treatments, Opia's technology platform holds significant potential, though it faces competition from established players and requires successful regulatory and clinical validation. The conviction score of 65 reflects the promise of its pipeline balanced against the inherent uncertainties of a private, pre-revenue medical device company.

Upcoming Catalysts (preview)

• Q2 2026CE Mark Approval for Ocular Surface Diagnostic Device70% success
• Q3 2026Clinical Trial Initiation for Non-invasive Drug Delivery Platform60% success
• H2 2026Strategic Partnership with Major Ophthalmology Company50% success